Pharmacogenomics: The Promising Future of Clinical Therapeutics

被引:0
|
作者
Arafah, Azher [1 ]
机构
[1] King Saud Univ, Coll Pharm, Dept Clin Pharm, Riyadh 11451, Saudi Arabia
来源
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS | 2024年 / 38卷 / 03期
关键词
pharmacogenetics; pharmacogenomics; adverse drug reaction; drug transporters; gene variants; precision medicine; IMPLEMENTATION CONSORTIUM GUIDELINES; DRUG-METABOLIZING-ENZYMES; PERSONALIZED MEDICINE; BREAST-CANCER; GENETIC-CONTROL; CYP2C19; GENOTYPE; TRANSPORTER; ASSOCIATION; RESISTANCE; WARFARIN;
D O I
10.23812/j.biol.regul.homeost.agents.20243803.144
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pharmacogenomics (PGx), a rapidly evolving field at the intersection of pharmacology and genomics, has the potential to revolutionize medical practice by investigating how an individual's genetic makeup influences their response to drugs. By optimizing drug selection, dosage, and treatment strategies based on an individual's genetic profile, pharmacogenomics aims to improve therapeutic outcomes, minimize adverse reactions, and enhance healthcare efficiency. Recent advancements in high-throughput genotyping technologies and the availability of genomic data have paved the way for personalized and targeted therapies. This review highlights pharmacogenomics's fundamental principles, applications, and challenges, emphasizing its potential to transform clinical practice and patient care. The field has made significant progress in understanding the impact of genetic variants on drug response, ranging from monogenic to complex polygenic variants. However, the implementation of pharmacogenomics in public health institutions remains limited. With continuous advancements and increasing integration of genomics into medicine, pharmacogenomics is poised to play a crucial role in precision medicine, improving drug efficacy, minimizing toxicity, and driving advancements in drug discovery and development.
引用
收藏
页码:1809 / 1829
页数:21
相关论文
共 50 条
  • [31] Pharmacogenomics: the future of drug therapy
    Tsai, YJ
    Hoyme, HE
    CLINICAL GENETICS, 2002, 62 (04) : 257 - 264
  • [32] Pharmacogenetics and pharmacogenomics: are they still promising?
    Pirazzoli, A
    Recchia, G
    PHARMACOLOGICAL RESEARCH, 2004, 49 (04) : 357 - 361
  • [33] Clinical applications of pharmacogenomics guided warfarin dosing
    Pramod Mahajan
    Kristin S. Meyer
    Geoffrey C. Wall
    Heidi J. Price
    International Journal of Clinical Pharmacy, 2013, 35 : 359 - 368
  • [34] Pharmacogenomics: road to anticancer therapeutics nirvana?
    Desai, AA
    Innocenti, F
    Ratain, MJ
    ONCOGENE, 2003, 22 (42) : 6621 - 6628
  • [35] Pharmacogenomics in Solid Tumors: A Comprehensive Review of Genetic Variability and Its Clinical Implications
    Sanchez-Bayona, Rodrigo
    Catalan, Camila
    Cobos, Maria Angeles
    Bergamino, Milana
    CANCERS, 2025, 17 (06)
  • [36] Pharmacogenomics: Role in Medicines Approval and Clinical Use
    Novelli, G.
    Borgiani, P.
    Ciccacci, C.
    Di Daniele, N.
    Sirugo, G.
    Amati, M. Papaluca
    PUBLIC HEALTH GENOMICS, 2010, 13 (05) : 284 - 291
  • [37] Clinical applications of pharmacogenomics guided warfarin dosing
    Pramod Mahajan
    Kristin S. Meyer
    Geoffrey C. Wall
    Heidi J. Price
    International Journal of Clinical Pharmacy, 2011, 33 : 10 - 19
  • [38] Enhancing clinical research with pharmacogenomics: a practical perspective
    Zhang, Xiaolong Tom
    Blacutt, Jacob
    Lloyd, Thomas
    Mencer, Mike
    Pratt, Vicky
    Kotha, Jayaprakash
    Sheeran, Lona
    Adcock, Sherilyn
    BIOANALYSIS, 2025, 17 (06) : 399 - 411
  • [39] Clinician perspectives on using pharmacogenomics in clinical practice
    Unertl, Kim M.
    Field, Julie R.
    Price, Lisa
    Peterson, Josh F.
    PERSONALIZED MEDICINE, 2015, 12 (04) : 339 - 347
  • [40] Clinical applications of pharmacogenomics guided warfarin dosing
    Mahajan, Pramod
    Meyer, Kristin S.
    Wall, Geoffrey C.
    Price, Heidi J.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2011, 33 (01) : 10 - 19